ATG4B and chronic myelogenous leukemia, BCR-ABL1 positive: In particular, it was found that knockdown of ATG4B by siRNA suppresses growth and survival of CD34+ chronic myelogenous leukemia (CML) progenitor cells and sensitises them to treatment with imatinib mesylate.